Cancer research continues to evolve, with new tools and techniques available to labs around the world. Molecular profiling has become an essential tool in cancer research over the recent years. Targeted analysis methods are now commonplace in cancer research, tailored to genetic or protein biomarkers that may drive a patient's tumor growth metastasis, treatment resistance, and recurrence.
Watch our engaging cancer research webinars featuring esteemed cancer research scientists and Thermo Fisher Scientific staff scientists, where they will share their expertise, latest findings, and innovative approaches in the field of oncology, providing valuable insights and fostering collaboration in advancing cancer research. Explore a diverse range of topics, from automation workflows to cutting-edge new research, and stay up to date with our latest advancements.
The first step in PCR- or NGS-based molecular profiling is sample collection. In cancer research, DNA or RNA extraction from tissue biopsies or solid tumors is standard. Liquid biopsies—which can detect circulating tumor-specific biomarkers in blood, plasma, or serum—have emerged as a promising, non-invasive alternative sample type for tumor molecular profiling. They also enable researchers to take multiple samples over time, allowing longitudinal tracking of cancer evolution.
Tumors release biomolecules into the bloodstream that can be collected and detected using a blood sample where the plasma is separated out and studied. The circulating tumor DNA (ctDNA) and intact circulating tumor cells (CTCs) are two of the markers targeted during a liquid biopsy.
Cell-free DNA plays a crucial role in cancer research due to its potential as a non-invasive biomarker for cancer detection, monitoring, and treatment. By analyzing the genetic alterations present in cfDNA, researchers can gain insights into the genetic landscape of tumors and identify specific mutations or alterations associated with different types of cancer.
Circulating tumor cell tests, also referred to as CTC tests, are liquid biopsy tests which look for whole tumor cells found in the bloodstream. These cells work as metastasis agents that can lead to the growth of additional tumors in sites other than that of the primary tumor and serve as a potential biomarker for cancer detection. CTC tests offer a non-invasive approach to study tumor dynamic, enabling early detection, improved understanding of metastasis, and the potential for targeted therapies.
Exosomes are integral to intercellular communication through their ability to transport and transfer biomolecules including proteins, nucleic acids, and lipids, between cells. This makes exosomes a potential disseminator of cancer-related factors, making them valuable for diagnostic, prognostic, and therapeutic purposes. Their unique properties make them promising targets for developing novel diagnostic tools and therapeutic strategies in the field of oncology.
To analyze solid tumor cancer using FFPE samples, several techniques are employed. These include histopathological examination, immunohistochemistry (IHC), polymerase chain reaction (PCR), next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH). These techniques allow for the detection of specific genetic alterations, such as mutations, gene amplifications, or chromosomal rearrangements.
For Research Use Only. Not for use in diagnostic procedures.